Key clinical point: Tumor markers can be used to detect relapse in patients with CNS nongerminomatous germ cell tumors.
Major finding: Among evaluable patients, 92% of relapses were detectable by tumor markers.
Study details: A pooled analysis of clinical trial data from 483 patients.
Disclosures: Dr. Fonseca reported having no disclosures, and the researchers disclosed no funding for this study.
Fonseca A et al. ASCO 2020, Abstract 2503.